Live tape
Top 8, mentions 7d17,305MSFT3,274 mentions▲ +0.08GOOGL2,648 mentions▲ +0.05META2,209 mentions▲ +0.04AAPL2,204 mentions▲ +0.07SPCX1,987 mentions▲ +0.06SNDK1,823 mentions▲ +0.06NVDA1,742 mentions▲ +0.07QQQ1,418 mentions▲ +0.04

Equity · Healthcare

AMRX

Amneal Pharmaceuticals, Inc. · NasdaqGS

$18.77 +4.25% 1D Finazon · prior-day close · Jul 28, 2026
Price · Chart Chart by TradingView
Track this symbol on TradingView

The chart above plots the price of AMRX over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 63 sessions over that window: $12.81 on 1 May 2026 through $18.77 on 28 July 2026. Finazon · prior-day close.

Market cap $6.0B
P/E (TTM) 60.5
52-week range $7.83 – $18.77
Avg volume 482.5K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Jul 29, 2026

AMRX insider trades

SEC Form 4 · last 90 days · newest reported trade 11 May 2026
Open-market buys 0
Open-market sells 1
Net sold $451K
Non-trade filings 8
Date Insider Type Shares Value
11 May 2026 Autor Deborah M. Director Sell 34,819 $451K
Compensation mechanics (8 filings)

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
07 May 2026 Yanai Shlomo Director Option exercise 34,819
07 May 2026 MEISTER PAUL M Director Option exercise 48,747
07 May 2026 Nark Ted C Director Option exercise 34,819
07 May 2026 Kiely John Director Option exercise 34,819
07 May 2026 Patel Gautam Director Option exercise 34,819
07 May 2026 George Jeffrey P. Director Option exercise 34,819
07 May 2026 Autor Deborah M. Director Option exercise 34,819
07 May 2026 BUCHI J KEVIN Director Option exercise 34,819

AMRX reported financials

SEC EDGAR XBRL

AMRX reported revenue of $3.0B for the fiscal year ended 31 Dec 2025. Net income over the same period was $72.1M.

Figure Reported Period
Revenue $3.0B 31 Dec 2025 fiscal year
Net income $72.1M 31 Dec 2025 fiscal year
Diluted EPS $0.22 31 Dec 2025 fiscal year
Total assets $3.5B 31 Mar 2026 at period end
Total equity −$45.4M 31 Mar 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 31 Mar 2026

AMRX earnings

SEC EDGAR
Date Period EPS Revenue
31 Mar 2026 Q1 2026 $0.19 —
31 Dec 2025 FY 2025 $0.22 —
30 Sep 2025 Q3 2025 $0.01 —
30 Jun 2025 Q2 2025 $0.07 —

Reported figures & scheduled dates · SEC EDGAR filings

AMRX institutional holders

SEC Form 13F

9 of the 45 institutional funds we track reported a AMRX position for the quarter ended 31 Mar 2026 — a combined $53.2M; the latest of those filings landed 15 May 2026.

Fund Action Shares Value
D. E. Shaw & Co. Trimmed −35.4% shares 1,719,954 $21.4M
AQR Capital Management Held (±25%) −17.3% shares 864,792 $10.7M
Citadel Advisors Trimmed −90.7% shares 577,419 $7.2M
Millennium Management Trimmed −89.0% shares 369,733 $4.6M
Two Sigma Investments Held (±25%) −6.1% shares 282,677 $3.5M
Renaissance Technologies Added +1,586.8% shares 276,637 $3.4M
Balyasny Asset Management Trimmed −88.5% shares 79,123 $983K
Point72 Asset Management New position 78,105 $971K
Man Group Trimmed −54.9% shares 28,358 $352K
Tudor Investment Corp Exited

Source: SEC EDGAR 13F filings

AMRX fails-to-deliver

SEC CNS data

On 18 Jun 2026, 25 shares of AMRX failed to deliver (about $407).

Settlement date Shares failed Notional % of shares out
18 Jun 2026 25 $407 <0.001%
15 Jun 2026 6 $97 <0.001%

Source: SEC fails-to-deliver (CNS) data